Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998773239> ?p ?o ?g. }
- W1998773239 endingPage "1979" @default.
- W1998773239 startingPage "1967" @default.
- W1998773239 abstract "Background: Guanfacine hydrochloride is an α2a-adrenoreceptor agonist found to be effective in the treatment of attention-deficit/hyperactivity disorder (ADHD). Because the available immediate-release formulation requires multiple daily dosing and has been associated with rebound hypertension on abrupt cessation, an extended-release (ER) formulation has been developed for study of efficacy and tolerability parameters in patients with ADHD. Objective: This trial was primarily undertaken to determine the effect on blood pressure (BP) of abrupt cessation versus taper-down of guanfacine ER. Methods: This Phase I, randomized, double-blind, placebo-controlled, dose-escalation trial was conducted at MDS Pharma Services, Lincoln, Nebraska. Male and female healthy young-adult (aged 19-24 years) volunteers were included. Subjects were randomly assigned to receive guanfacine ER as follows. Abrupt-cessation and taper-down groups both received guanfacine ER at forced titration: 1 mg on days 1 to 4, 2 mg on days 5 to 8, 3 mg on days 9 to 12, and 4 mg on days 13 to 16. The abrupt-cessation group then received placebo daily on days 17 to 32. The taper-down group began the following taper-down schedule: 3 mg on days 17 to 20, 2 mg on days 21 to 24, 1 mg on days 25 to 30, and placebo on days 31 to 32. Placebo was administered daily to the subjects in the placebo group (days 1–32). All doses were given in the morning. Tolerability was assessed before (at the 8-hour baseline visit), during (approximately every 4 days and during 48-hour confinements at days 17/18 and 31/32), and 7 days after the study and included assessment of BP and pulse, 12-lead electrocardiography (ECG), and laboratory assays. Adverse events (AEs) were also tracked every 4 days beginning on day 5 and 7, 14, and 30 days poststudy by recording responses and follow-up to a nonleading question about how the patient was feeling that day. Results: Forty-five subjects were enrolled in the study (15 in each group), and 35 subjects completed it. The mean age of study participants was 22 years, 87% were white, and the ratio of women to men was 2:1. There were no marked differences between groups regarding age, sex, or race. Compared with the taperdown group, the abrupt-cessation group did not exhibit a clinically significant elevation of systolic BP (SBP) or diastolic BP (DBP) or other tolerability parameters, including AEs. Significant differences in BP were observed on days 17/18 (first day of abrupt cessation) and 31/32, but the overall means were not statistically different. The SBP decreases were −7.55% (−8.84 mm Hg) in the abrupt-cessation group and −8.33% (−9.69 mm Hg) in the taper-down group. The DBP decreases were −9.14% (−6.17 mm Hg) in the abrupt-cessation group and −9.94% (−6.59 mm Hg) in the taper-down group. There were no statistically significant or clinically important differences in change or percentage change in pulse from baseline to day 31/32 between the taper-down and placebo groups (least squares mean difference, 2.26 bpm). None of the subjects experienced bradycardia. No clinically important treatment related trends were noted in the clinical laboratory, ECG, or physical examination findings, including vital signs. No serious treatment-emergent AEs were reported in this study. Overall, 124 treatment-emergent AEs were reported in 29 (64%) subjects. Treatment-emergent AEs were reported in 14 (93.3%) of 15 subjects in the abrupt-cessation group, 8 (53.3%) of 15 subjects in the taper-down group, and 7 (46.7%) of 15 subjects in the placebo group. Headache was the most common AE reported in the abrupt-cessation (46.7%) and placebo (13.3%) groups. For the taper down group, it was dry mouth (26.7%). All AEs were classified as mild or moderate. Conclusion: In this small study group of healthy, young-adult volunteers, guanfacine ER at doses up to 4 mg/d was abruptly discontinued without significant increases in SBP or DBP or other tolerability parameters, including AEs, compared with taper." @default.
- W1998773239 created "2016-06-24" @default.
- W1998773239 creator A5027354439 @default.
- W1998773239 creator A5045218676 @default.
- W1998773239 creator A5067786420 @default.
- W1998773239 date "2007-09-01" @default.
- W1998773239 modified "2023-09-23" @default.
- W1998773239 title "Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years" @default.
- W1998773239 cites W1501686051 @default.
- W1998773239 cites W1507229193 @default.
- W1998773239 cites W1522997416 @default.
- W1998773239 cites W1965392517 @default.
- W1998773239 cites W1968161022 @default.
- W1998773239 cites W1970116189 @default.
- W1998773239 cites W1972639908 @default.
- W1998773239 cites W1980253766 @default.
- W1998773239 cites W1982166376 @default.
- W1998773239 cites W2000247756 @default.
- W1998773239 cites W2002691701 @default.
- W1998773239 cites W2015540486 @default.
- W1998773239 cites W2018897037 @default.
- W1998773239 cites W2019101336 @default.
- W1998773239 cites W2032807853 @default.
- W1998773239 cites W2033304004 @default.
- W1998773239 cites W2039755273 @default.
- W1998773239 cites W2042348492 @default.
- W1998773239 cites W2053758131 @default.
- W1998773239 cites W2088550173 @default.
- W1998773239 cites W2109935740 @default.
- W1998773239 cites W2113759011 @default.
- W1998773239 cites W2122625420 @default.
- W1998773239 cites W2126915357 @default.
- W1998773239 cites W2150855904 @default.
- W1998773239 cites W2158782477 @default.
- W1998773239 cites W2159011576 @default.
- W1998773239 cites W2164549762 @default.
- W1998773239 cites W2169197323 @default.
- W1998773239 cites W2182541551 @default.
- W1998773239 cites W2413440761 @default.
- W1998773239 cites W2563007477 @default.
- W1998773239 cites W3090293687 @default.
- W1998773239 cites W2740729911 @default.
- W1998773239 doi "https://doi.org/10.1016/j.clinthera.2007.09.020" @default.
- W1998773239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18035196" @default.
- W1998773239 hasPublicationYear "2007" @default.
- W1998773239 type Work @default.
- W1998773239 sameAs 1998773239 @default.
- W1998773239 citedByCount "17" @default.
- W1998773239 countsByYear W19987732392013 @default.
- W1998773239 countsByYear W19987732392014 @default.
- W1998773239 countsByYear W19987732392015 @default.
- W1998773239 countsByYear W19987732392017 @default.
- W1998773239 countsByYear W19987732392018 @default.
- W1998773239 countsByYear W19987732392022 @default.
- W1998773239 crossrefType "journal-article" @default.
- W1998773239 hasAuthorship W1998773239A5027354439 @default.
- W1998773239 hasAuthorship W1998773239A5045218676 @default.
- W1998773239 hasAuthorship W1998773239A5067786420 @default.
- W1998773239 hasConcept C126322002 @default.
- W1998773239 hasConcept C142724271 @default.
- W1998773239 hasConcept C168563851 @default.
- W1998773239 hasConcept C19720800 @default.
- W1998773239 hasConcept C197934379 @default.
- W1998773239 hasConcept C204787440 @default.
- W1998773239 hasConcept C27081682 @default.
- W1998773239 hasConcept C2777288759 @default.
- W1998773239 hasConcept C2778375690 @default.
- W1998773239 hasConcept C2778399450 @default.
- W1998773239 hasConcept C2780815205 @default.
- W1998773239 hasConcept C42219234 @default.
- W1998773239 hasConcept C71924100 @default.
- W1998773239 hasConcept C84393581 @default.
- W1998773239 hasConceptScore W1998773239C126322002 @default.
- W1998773239 hasConceptScore W1998773239C142724271 @default.
- W1998773239 hasConceptScore W1998773239C168563851 @default.
- W1998773239 hasConceptScore W1998773239C19720800 @default.
- W1998773239 hasConceptScore W1998773239C197934379 @default.
- W1998773239 hasConceptScore W1998773239C204787440 @default.
- W1998773239 hasConceptScore W1998773239C27081682 @default.
- W1998773239 hasConceptScore W1998773239C2777288759 @default.
- W1998773239 hasConceptScore W1998773239C2778375690 @default.
- W1998773239 hasConceptScore W1998773239C2778399450 @default.
- W1998773239 hasConceptScore W1998773239C2780815205 @default.
- W1998773239 hasConceptScore W1998773239C42219234 @default.
- W1998773239 hasConceptScore W1998773239C71924100 @default.
- W1998773239 hasConceptScore W1998773239C84393581 @default.
- W1998773239 hasIssue "9" @default.
- W1998773239 hasLocation W19987732391 @default.
- W1998773239 hasLocation W19987732392 @default.
- W1998773239 hasOpenAccess W1998773239 @default.
- W1998773239 hasPrimaryLocation W19987732391 @default.
- W1998773239 hasRelatedWork W1966047811 @default.
- W1998773239 hasRelatedWork W1998773239 @default.
- W1998773239 hasRelatedWork W2003042623 @default.
- W1998773239 hasRelatedWork W202460821 @default.
- W1998773239 hasRelatedWork W2030348591 @default.
- W1998773239 hasRelatedWork W2056817651 @default.
- W1998773239 hasRelatedWork W2068849886 @default.